Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement Jan 09, 2023 7:00am EST
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings Dec 08, 2022 7:00am EST
Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Nov 16, 2022 8:00am EST
Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator Nov 09, 2022 7:02am EST
Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting Oct 24, 2022 7:00am EDT
Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference Sep 07, 2022 7:00am EDT
